SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 02/19/2019
Entire Document
 

 

4 Transaction Overview ▪ Headquartered in Morristown, New Jersey, Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription medication, primarily for the U.S. market ▪ Pernix operates through four primary assets/segments: • Zohydro ® ER with BeadTek ® – Extended release (ER) oral formulation of hydrocodone bitartrate designed with abuse - deterrent technology for the treatment of chronic pain (31% of 2018E Net Sales) • Silenor ® – Low dose doxepin for the treatment of insomnia characterized by difficulties with sleep maintenance (26% of 2018E Net Sales) • Treximet ® – Fixed - dose combination of sumatriptan and naproxen with RT Technology TM for the treatment of acute migraine attacks (34% of 2018E Net Sales) • Generics / Other – Mix of marketed generic and branded products for various indications (9% of 2018E Net Sales) ▪ In addition, Pernix owns a 10% interest in Nalpropion Pharmaceuticals, Inc. (“ Nalpropion ”), which owns worldwide rights to Contrave ® , a market - leading weight loss medication, and Pernix manages Nalpropion in exchange for a management fee plus expense reimbursement ▪ For 2018E, the Company expects to generate $91.1M of Net Sales and $7.9M of Adjusted EBITDA ▪ The Company has retained Guggenheim Securities, LLC (“Guggenheim Securities”) as its investment banker to seek proposals for a strategic investment in Pernix or an acquisition of all or a portion of the Company’s assets